Bioanalytical method development of lipids, peptides and small molecules by LC-MS/MS


Understanding biodistribution is critical for evaluation of bioequivalence, bioavailability, and toxicity of a drug substance and in some cases for excipients such as cationic lipids, which play a vital role in the delivery of gene therapies. Residual drug substances or excipients are analyzed in various biological matrices such as blood, plasma, serum, and tissues. The choice of matrix is mainly dependent on the route of administration.


Key Learning Objectives:

  • Approaches taken during LC-MS/MS method development to ensure good method sensitivity
  • Optimization of sample preparation with an emphasis on protein precipitation technique
  • Ensuring method robustness before moving to validation


Who Should Attend:

  • Analytical Scientists
  • CMC Executives 




Uday Velagapudi, Ph.D.
Scientist III/ Group Leader

Uday Velagapudi


Uday Velagapudi is a Scientist III/Group Leader of Pharmaceutical Sciences at Pace® Life Sciences, an integrated CMC drug product development CRO. Uday is an SME focusing on method development for bioanalytical quantitation, small molecule and metabolite characterization, protein characterization and host-cell protein analysis using low and high-resolution LC-MS systems. Uday is the author or co-author of eight publications in reputable journals such as Science and Journal of medicinal chemistry and received his PhD in Medicinal and Pharmaceutical Chemistry from St. John’s University, NY.



Find Additional CMC Offerings

Consider Our Clinical Supplies Manufacturing